Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261086 | 1.00 | ALDH1A1 (0.36) | ALDH1A1KDM4EMEN1GFERKMT2A | |
| SCHEMBL1826587 | 0.97 | KDM4E (0.33) | ALDH1A1KDM4EMEN1GFERKMT2A | |
| SCHEMBL3372134 | 0.84 | — | — | |
| SCHEMBL7274455 | 0.83 | KDM4E (0.32) | ALDH1A1KDM4EMEN1GFERKMT2A | |
| SCHEMBL3373140 | 0.81 | — | — | |
| SCHEMBL11073647 | 0.78 | CYP2D6 (0.31) | ALDH1A1 | |
| SCHEMBL3375790 | 0.78 | CNR2 (0.33) | KDM4EMEN1KMT2AHPGD | |
| SCHEMBL3376121 | 0.74 | SMN1; SMN2 (0.31) | ALDH1A1 | |
| SCHEMBL18393768 | 0.74 | — | — | |
| SCHEMBL3375956 | 0.71 | TSHR (0.60) | ALDH1A1KDM4EKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | claimed |
| WO-2021024141-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | LI XIAOXIANG (CN) | 2021-02-11 | — | — | WO | claimed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | claimed |
| CN-107074866-B | Pyrimido-pyrrole compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2019-06-07 | — | — | CN | claimed |
| EP-1307458-B1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL LAB (ES) | 2007-10-03 | — | — | EP | claimed |
| US-7060824-B2 | Pyrrolotriazolopyrimidinone derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-06-13 | — | — | US | claimed |
| US-7034016-B2 | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-04-25 | — | — | US | claimed |
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | VIDAL JUAN BERNAT (ES) | 2004-01-29 | — | — | US | claimed |
| EP-1198464-B1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2003-10-08 | — | — | EP | claimed |
| EP-1307458-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2003-05-07 | — | — | EP | claimed |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-03-27 | — | — | US | claimed |
| EP-1198464-A1 | 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2002-04-24 | — | — | EP | claimed |
| WO-2002012246-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2002-02-14 | — | — | WO | claimed |
| WO-2001007441-A1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2001-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | HYOU1, CHN2, PURB | ALDH1A1 1064/4885KDM4E 4355/4885MEN1 2214/4885 |
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | PDE5A, PDE3A, PDE2A | ALDH1A1 966/4885KDM4E 534/4885MEN1 4622/4885 |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | ALDH1A1 979/4885KDM4E 3393/4885MEN1 2289/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | ALDH1A1 979/4885KDM4E 3393/4885MEN1 2289/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | ALDH1A1 3469/4885KDM4E 4200/4885MEN1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.